Pan J, Xiong D, Zhang Q, Palen K, Shoemaker R, Johnson B, et al. Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Front Immunol. 2023;14:1036563 pubmed publisher

Song X, Tang W, Peng H, Qi X, Li J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest New Drugs. 2021;: pubmed publisher

Castellan M, Guarnieri A, Fujimura A, Zanconato F, Battilana G, Panciera T, et al. Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. Nat Cancer. 2021;2:174-188 pubmed publisher

Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, et al. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Sci. 2021;112:1963-1974 pubmed publisher

Quintanal Villalonga Á, Molina Pinelo S, Cirauqui C, Ojeda Márquez L, Marrugal A, Suarez R, et al. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. J Thorac Oncol. 2019;14:641-655 pubmed publisher

Song X, Qi X, Wang Q, Zhu W, Li J. A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Am J Cancer Res. 2017;7:1884-1898 pubmed

Ku B, Bae Y, Koh J, Sun J, Lee S, Ahn J, et al. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Invest New Drugs. 2016;34:407-15 pubmed publisher

Yuza Y, Glatt K, Jiang J, Greulich H, Minami Y, Woo M, et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther. 2007;6:661-7 pubmed